All In Biotech

Drug Trial Radar · NCT00228982

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections

Last checked: Nov 20, 2026Latest source record: Jul 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 784 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

784

Actual

Start

Oct 2004

Primary completion

Dec 2005

Study completion Dec 2005

Sponsor

Lead sponsor
Basilea PharmaceuticaIndustry
Sponsor type
Industry
First posted
Sep 29, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections.

Conditions

  • Skin Diseases, Infectious
  • Skin Diseases, Bacterial
  • Staphylococcal Skin Infections

Interventions

  • Ceftobiprole medocarilDrug

  • VancomycinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical outcome (cure, failure, not evaluable) at 7-14 days after the end of therapy.Time frame: 7 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.